Prosecution Insights
Last updated: July 17, 2026
Application No. 18/838,531

GLUCOSE DIFFUSION CONTROL LAYER SOLUTION FOR CONTINUOUS BLOOD GLUCOSE-MEASURING BIOSENSOR, GLUCOSE DIFFUSION CONTROL LAYER FOR CONTINUOUS BLOOD GLUCOSE-MEASURING BIOSENSOR COMPRISING SAME, AND CONTINUOUS BLOOD GLUCOSE-MEASURING BIOSENSOR COMPRISING SAME

Non-Final OA §103
Filed
Aug 14, 2024
Priority
Feb 16, 2022 — RE 10-2022-0020018 +1 more
Examiner
TOMBERS, JOSEPH A
Art Unit
Tech Center
Assignee
Sd Biosensor Inc.
OA Round
1 (Non-Final)
47%
Grant Probability
Moderate
1-2
OA Rounds
2y 0m
Est. Remaining
77%
With Interview

Examiner Intelligence

Grants 47% of resolved cases
47%
Career Allowance Rate
91 granted / 193 resolved
-12.8% vs TC avg
Strong +30% interview lift
Without
With
+30.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
41 currently pending
Career history
251
Total Applications
across all art units

Statute-Specific Performance

§101
2.3%
-37.7% vs TC avg
§103
85.8%
+45.8% vs TC avg
§102
10.8%
-29.2% vs TC avg
§112
1.0%
-39.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 193 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Information Disclosure Statement The information disclosure statement (IDS) submitted on January 27, 2026; August 14, 2024 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Drawings The drawings filed on August 14, 2024 are accepted. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1 and 5-7 are rejected under 35 U.S.C. 103 as being unpatentable over Staib et al. (US 10.422,765 B2) (“Staib”) in view of Mamidi et al. (US 2024/0350485 A1) (“Mamidi”). Regarding claim 1, Staib discloses A glucose diffusion control layer solution for a continuous blood glucose-measuring biosensor, comprising (Abstract and entire document): a hydrophilic material; and a hydrophobic material (Col. 3 line 54 -col. 4, “As noted above, the diffusion barrier includes a block copolymer, such as a single block copolymer having at least one hydrophilic block and at least one hydrophobic block.”), wherein the hydrophobic material comprises a styrene block copolymer (Claim 25, styrene block copolymer as the hydrophobic material). Staib fails to disclose wherein the hydrophilic material comprises an aliphatic polyether-based thermoplastic polyurethane, and However, in the same field of endeavor, Mamidi teaches wherein the hydrophilic material comprises an aliphatic polyether-based thermoplastic polyurethane, and It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention, to modify the solution as taught by Staib to include wherein the hydrophilic material comprises an aliphatic polyether-based thermoplastic polyurethane as taught by Mamidi to have desirable properties ([0154], “Accordingly, it can be advantageous to utilize a combination of two different polymeric materials, rather than making the system housing entirely of the water-swelling hydrophilic, drug-permeable second material, to achieve desired mechanical properties of the tube.”). Regarding claim 5, Staib as modified discloses The glucose diffusion control layer solution of claim 1, Staib discloses wherein the hydrophilic material and hydrophobic material have a weight ratio of 1:0.1 to 4 (Col. 12 discussing ratio of hydrophilic to hydrophobic blocks). It would have been obvious to one of ordinary skill in the art, through routine optimization, to determine the optimal ratio, including a weight ratio of 1:0.1 to 4. Where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). Since applicant has not disclosed that this limitation solves any stated problem or is for any particular purpose and it appears that the device would perform equally well with either designs. Absent a teaching as to criticality that the weight ratio of 1:0.1 to 4, this particular arrangement is deemed to have been known by those skilled in the art since the instant specification and evidence of record fail to attribute any significance (novel or unexpected results) to a particular arrangement. Regarding claim 6, Staib as modified discloses A glucose diffusion control layer for a continuous blood glucose-measuring biosensor, Staib as modified further discloses which is prepared by drying the glucose diffusion control layer solution of claim 1 (Staib, Abstract and entire document, diffusion control layer for analyte sensors). Regarding claim 7, Staib as modified discloses A continuous blood glucose-measuring biosensor, Staib as modified further discloses comprising the glucose diffusion control layer of claim 6 (Staib, Abstract and entire document, diffusion control layer for analyte sensors). Claims 2-4 are rejected under 35 U.S.C. 103 as being unpatentable over Staib in view of Mamidi in further view of Simpson et al. (US 2019/0290474 A1) (”Simpson”). Regarding claims 2-4, Staib as modified discloses The glucose diffusion control layer solution of claim 1, wherein the aliphatic polyether-based thermoplastic polyurethane has a specific gravity of 1.0 to 1.2 g/cm3 according to the ASTM D792 measurement method, and a shore hardness of 78 to 88A according to the ASTM D2240 measurement method, and wherein the aliphatic polyether-based thermoplastic polyurethane has a flexural modulus of 2,400 to 3,400 psi according to the ASTM D790 measurement method, an ultimate tensile of 1,700 to 2,700 psi in a dry state and an ultimate tensile of 900 to 1,900 psi in a wet state according to the ASTM D412 measurement method, and an ultimate elongation of 540 to 1,540 psi in a dry state and an ultimate elongation of 320 to 920 psi in a wet state according to the ASTM D412 measurement method (Mamidi: [0121 – 0130] properties of Tecophilic HP-93A-100.). Staib as modified fails to disclose wherein the styrene block copolymer has a specific gravity of 0.9 to 1.1 g/cm3 according to the ISO 1183-1 measurement method, and a shore hardness of 60 to 80A according to the ISO 48- 4 measurement method. wherein the styrene block copolymer has a tensile strength of 8.2 to 10.2 MPa according to the ISO 37 measurement method, an elongation at break of 414 to 614% according to the ISO 37 measurement method, and a tear strength of 15 to 25 N/mm according to the ISO 34-1 measurement method. However, in the same field of endeavor, Simpson teaches wherein the styrene block copolymer has a specific gravity of 0.9 to 1.1 g/cm3 according to the ISO 1183-1 measurement method, and a shore hardness of 60 to 80A according to the ISO 48- 4 measurement method. wherein the styrene block copolymer has a tensile strength of 8.2 to 10.2 MPa according to the ISO 37 measurement method, an elongation at break of 414 to 614% according to the ISO 37 measurement method, and a tear strength of 15 to 25 N/mm according to the ISO 34-1 measurement method (FIG. 6 and [0039] and [0127 – [0130], Thermolast, properties of). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention, to modify the solution as taught by Staib as modified to include wherein the styrene block copolymer has a specific gravity of 0.9 to 1.1 g/cm3 according to the ISO 1183-1 measurement method, and a shore hardness of 60 to 80A according to the ISO 48- 4 measurement method. wherein the styrene block copolymer has a tensile strength of 8.2 to 10.2 MPa according to the ISO 37 measurement method, an elongation at break of 414 to 614% according to the ISO 37 measurement method, and a tear strength of 15 to 25 N/mm according to the ISO 34-1 measurement method as taught by Simpson to obtain desired hardness/qualities of the material ([0127 – 0130]). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOSEPH A TOMBERS whose telephone number is (571)272-6851. The examiner can normally be reached on M-TH 7:00-16:00, F 7:00-11:00(Eastern). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert Chen can be reached on 571-272-3672. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see https://ppair-my.uspto.gov/pair/PrivatePair. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JOSEPH A TOMBERS/Examiner, Art Unit 3791
Read full office action

Prosecution Timeline

Aug 14, 2024
Application Filed
May 16, 2025
Response after Non-Final Action
Jul 02, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12672819
REFERENCE STIMULUS
4y 8m to grant Granted Jul 07, 2026
Patent 12667283
SENSOR UNIT, BODY FLUID MONITORING DEVICE AND METHOD FOR DETECTING AN ANALYTE
5y 1m to grant Granted Jun 30, 2026
Patent 12667299
METHODS AND APPARATUS FOR TRIGGERING A STIMULUS FOR EVOKED BRAIN RESPONSE ANALYSIS
4y 9m to grant Granted Jun 30, 2026
Patent 12648707
System and Method for Differentiation of Adipose Tissue from Scar Tissue During Electrophysiological Mapping
8y 3m to grant Granted Jun 09, 2026
Patent 12640268
AUXILIARY ASSESSMENT METHOD AND SYSTEM FOR CARDIAC FUNCTION
2y 10m to grant Granted May 26, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
47%
Grant Probability
77%
With Interview (+30.2%)
3y 11m (~2y 0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 193 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month